Small Pharma Inc. confirmed that the first patient has been dosed in its Phase I study comparing the profiles of intramuscular (‘IM') and intravenous (‘IV'), the company's proprietary formulation of N, N-dimethyltryptamine (‘DMT'). The goal of the study, which is being conducted at Hammersmith Medicines Research Ltd. in the United Kingdom, is to compare the safety, tolerability, pharmacokinetics and pharmacodynamics of SPL026 delivered via IM versus IV administration, in up to 14 healthy volunteers.